Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-08-26 Call Transcript
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Transcript of Q1 FY2022 Earnings Conference Call.
Call Transcript Classification · 100% confidence The document is a transcript of the Q1 FY2022 earnings conference call for Lupin Limited, dated August 11, 2021, as indicated by the title and the detailed Q&A session with management discussing quarterly financial performance, business outlook, and operational details. It includes management commentary, financial figures, and responses to analyst questions, which are typical features of an earnings call transcript. The document is not a brief announcement or a summary but a full transcript of the call. Therefore, the appropriate classification is 'Call Transcript' (CT).
2021-08-26 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press note announcing the launch of a pharmaceutical product (Luforbec 100/6 pMDI) by Lupin Limited in the UK, following regulatory approval by the MHRA. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content focuses on product launch information, market potential, and company background. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory disclosure announcement rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure.
2021-08-24 English
Lupin Launches Luforbec® 100/6 µg pMDI, first branded generic alternative to Fostair® 100/6 µg pMDI for treatment of Asthma & COPD, in the UK.
Regulatory Filings Classification · 95% confidence The document is a press note announcing the launch of a pharmaceutical product (Luforbec 100/6 pMDI) by Lupin Limited in the UK, following regulatory approval by the MHRA. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on product launch details, market potential, and company background, without any financial statements, earnings data, or detailed financial analysis. It is not a financial report, earnings release, or regulatory filing related to financial performance. It is a corporate announcement related to product launch and regulatory approval, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-08-24 English
Disclosure in respect of allotment of 57696 shares under Lupin Employees Stock Option Plan.
Share Issue/Capital Change Classification · 95% confidence The document is a letter addressed to BSE Limited disclosing the allotment of shares under the Employee Stock Option Plan (ESOP) pursuant to SEBI Listing Regulations. It reports the allotment of 57,696 fully paid equity shares and the resulting increase in the company's issued and paid-up capital. The content is an announcement of a capital change due to share allotment under ESOP, not a full financial report or detailed analysis. The document length is short (1261 characters) and it is a regulatory disclosure about share allotment. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2021-08-19 English
ESOP/ESOS/ESPS
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for omitted pictures and no textual content or context to identify any specific filing type. The document length is very short (126 characters) and lacks any substantive information, titles, or keywords related to financial reports, announcements, or regulatory filings. Given the absence of any identifiable content, the document cannot be classified into any specific category other than the fallback category for miscellaneous or unclassifiable filings.
2021-08-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or management discussion. The document length is 4008 characters, which is relatively short and typical for a press release. There is no financial data, no meeting materials, no voting results, no audit information, no legal proceedings, no capital changes, and no executive changes. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2021-08-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.